Related Experiment Video

Updated: Jul 11, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

[Anticoagulation for stroke prevention. An update]

H C Koennecke1

  • 1Gefässzentrum Berlin, Abteilung für Neurologie, Ev. Krankenhaus Königin Elisabeth Herzberge, Berlin. h.koennecke@keh-berlin.de

Der Nervenarzt
|September 14, 2007
PubMed

Insights

Anticoagulation is crucial for preventing stroke in the growing population of elderly patients with atrial fibrillation. This review covers new antithrombotic treatments and risk assessment to encourage anticoagulation use in this demographic.

Area of Science:

  • Cardiology
  • Geriatrics
  • Pharmacology

Context:

  • Projected rise in atrial fibrillation prevalence necessitates improved stroke prevention strategies.
  • Elderly patients with atrial fibrillation face increased risk of stroke and systemic embolism.
  • Current reluctance towards anticoagulation in older adults requires addressing.

Purpose:

  • To summarize recent advancements in antithrombotic therapies for atrial fibrillation.
  • To review updated risk stratification methods for stroke prevention in atrial fibrillation.
  • To encourage the adoption of anticoagulation in elderly patients with atrial fibrillation.

Summary:

  • Recent developments in antithrombotic treatments offer improved stroke prevention for atrial fibrillation.
  • Risk stratification tools aid in identifying elderly patients who would benefit most from anticoagulation.
  • Addressing hesitancy towards anticoagulation is key to managing atrial fibrillation risks in older populations.

Impact:

  • Improved stroke prevention outcomes for the aging population with atrial fibrillation.
  • Enhanced clinical decision-making regarding antithrombotic therapy in elderly patients.
  • Reduced burden of stroke and systemic embolism in a growing demographic.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Hemorrhagic Stroke ll: Pathophysiology01:29

Hemorrhagic Stroke ll: Pathophysiology

A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...